Literature DB >> 3265331

Cyclosporin A prevents the anti-murine antibody response to a monoclonal anti-tumour antibody in rabbits.

J A Ledermann1, R H Begent, K D Bagshawe.   

Abstract

Repeated therapy of cancer with mouse monoclonal antibodies frequently produces antibodies directed against the administered antibody. We have investigated the ability of cyclosporin A (CsA) and the use of ultracentrifuged antibody to prevent the formation of anti-antibodies in rabbits. Courses of CsA, 20 mgkg-1 day-1, were given intramuscularly for 6 days to rabbits and a mouse monoclonal anti-human chorionic gonadotrophin antibody was given intravenously on day 2 with or without ultracentrifugation to remove microaggregates. The whole course was repeated after an interval of two weeks. Rabbit anti-mouse antibody production was prevented in all 8 animals that were given CsA and ultracentrifuged preparation (non UC-W14). Anti-mouse antibody was produced by all the animals that were not given CsA. A further dose of mouse antibody eight weeks after CsA demonstrated that immunological recovery had occurred in all four animals re-challenged with non UC-W14 but only 3/7 animals given an UC-W14 preparation. This suggests that CsA and ultracentrifugation facilitate the induction of immunological tolerance. The complete suppression of antibody production which could be achieved justifies a clinical trial of CsA and ultracentrifugation of antibody.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3265331      PMCID: PMC2246811          DOI: 10.1038/bjc.1988.259

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  25 in total

1.  Biological effects of cyclosporin A: a new antilymphocytic agent.

Authors:  J F Borel; C Feurer; H U Gubler; H Stähelin
Journal:  Agents Actions       Date:  1976-07

2.  THE ANTIGENICITY OF AGGREGATED AND AGGREGATE-FREE HUMAN GAMMA-GLOBULIN FOR RABBITS.

Authors:  C E BIRO; G GARCIA
Journal:  Immunology       Date:  1965-04       Impact factor: 7.397

3.  Preventing antibody formation to anti-lymphocytic globulin in man.

Authors:  R D Rossen; W T Butler; J J Nora; D J Fernbach
Journal:  J Immunol       Date:  1971-01       Impact factor: 5.422

4.  Specific inactivation of antigen-reactive cells with 125I-labelled antigen.

Authors:  G L Ada; P Byrt
Journal:  Nature       Date:  1969-06-28       Impact factor: 49.962

5.  The effect of cyclosporin A on the primary and secondary immune responses in the rabbit.

Authors:  N J Lindsey; K R Harris; H B Norman; J L Smith; H A Lee; M Slapek
Journal:  Transplant Proc       Date:  1980-06       Impact factor: 1.066

6.  Effects of the new anti-lymphocytic peptide cyclosporin A in animals.

Authors:  J F Borel; C Feurer; C Magnée; H Stähelin
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

7.  Phase-I clinical trial of monoclonal antibody in treatment of gastrointestinal tumours.

Authors:  H F Sears; B Atkinson; J Mattis; C Ernst; D Herlyn; Z Steplewski; P Häyry; H Koprowski
Journal:  Lancet       Date:  1982-04-03       Impact factor: 79.321

8.  The effect of cyclosporin A on the primary immune response to allogeneic red cells in rabbits.

Authors:  G N Smith
Journal:  Immunology       Date:  1982-01       Impact factor: 7.397

9.  Effects of cyclosporine on the immune system of the mouse. II. Cyclosporine inhibits the effector function of primary T helper cells, but not helper cell priming.

Authors:  G G Klaus; A Kunkl
Journal:  Transplantation       Date:  1983-07       Impact factor: 4.939

10.  Extensive prolongation of rabbit kidney allograft survival after short-term cyclosporin-A treatment.

Authors:  C J Green; A C Allison
Journal:  Lancet       Date:  1978-06-03       Impact factor: 79.321

View more
  4 in total

1.  Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies.

Authors:  G B Sivolapenko; M Kanariou; R J Edwards; A A Epenetos; M A Ritter
Journal:  Br J Cancer       Date:  1989-10       Impact factor: 7.640

Review 2.  The First Bagshawe lecture. Towards generating cytotoxic agents at cancer sites.

Authors:  K D Bagshawe
Journal:  Br J Cancer       Date:  1989-09       Impact factor: 7.640

Review 3.  Clinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.

Authors:  K J Harrington; R G Vile; A Melcher; J Chester; H S Pandha
Journal:  Cytokine Growth Factor Rev       Date:  2010-03-12       Impact factor: 7.638

4.  Repeated antitumour antibody therapy in man with suppression of the host response by cyclosporin A.

Authors:  J A Ledermann; R H Begent; K D Bagshawe; S J Riggs; F Searle; M G Glaser; A J Green; R G Dale
Journal:  Br J Cancer       Date:  1988-11       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.